Natera and Illumina settle litigation, agree mutual licence

Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Natera accuses CareDx of infringing DNA testing patents

17 May 2022 Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.

Big Pharma

Invitae claims Natera infringed DNA patents

13 May 2021 Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.

Americas

Illumina to acquire Jeff Bezos-backed cancer testing company

23 September 2020 Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Natera and Illumina settle litigation, agree mutual licence

More on this story

Editor's picks

Editor's picks

More features